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Effect of Hyperbaric Oxygen 
on Hematopoietic Stem Cell 
Transplantation
Omar S. Aljitawi
Abstract
In this chapter the accumulated evidence that supports the role of hyper-
baric oxygen therapy (HBOT) in improving the process of hematopoietic stem/
progenitor cell (HSPC) homing, engraftment, and immune-reconstitution will 
be reviewed. The underlying mechanism by which HBO modulates erythropoi-
etin (EPO)/EPOR signaling to improve HSPC homing and engraftment will be 
described. Also the pre-clinical evidence and pilot clinical trial evidence that 
supports HBO role in improving HSPC homing and engraftment will be examined. 
Current and future clinical trial studies that stem from this concept will be detailed. 
Finally, areas that need future investigations to optimally utilize HBO in the field of 
HSPC transplantation will be described.
Keywords: hyperbaric oxygen therapy (HBOT), hematopoietic stem/progenitor 
cell (HSPC), homing and engraftment, hematopoietic stem/progenitor cell 
transplantation, pilot clinical trials, phase II clinical trials
1. Introduction
Allogeneic transplantation is the only curative approach for many hematologic 
malignant and nonmalignant disorders. Unfortunately, only 30% of patients will 
have a matched sibling donor [1]. However, well-matched donors (MUDs) are a 
suitable alternative for those who do not. In one study, well-matched MUDs were 
identified in 53% of those with Northern European ancestry, compared to only 21% 
of patients of other origin [2]. For patients without a histocompatible adult donor, 
transplant options include unrelated umbilical cord blood (UCB) transplantation  
or transplant from a haploidentical (haplo) donor [3]. Since the first successful 
UCB transplant in 1988 [4], UCB has been used as a graft source for over 40,000 
patients with both malignant and nonmalignant diseases [5, 6].
As a graft source for transplantation, UCB has several practical advantages 
including ease of procurement, absence of donor risks, reduced risk of transmis-
sible infections, and availability for immediate use [7]. UCB is also associated with 
a lower incidence of graft-versus-host disease (GVHD) despite HLA disparity [8]. 
Therefore, UCB extends the application of allogeneic transplant to ethnic minor-
ity populations who are underrepresented in donor registries [9]. Additionally, 
UCB transplantation is associated with reduced leukemia relapse in patients with 
evidence of minimal residual disease at time of transplant, suggesting a strong 
graft-versus-leukemia effect [10]. However, UCB units in themselves are limited in 
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cell doses available for optimal transplantation in adults. UCB stem cells also dem-
onstrate defects in homing to the bone marrow (BM), implicating delayed recovery 
of neutrophil and platelet count and achieved engraftment, resulting in higher 
rates of graft failure [11]. This prolonged time to engraftment is also associated 
with delayed immune reconstitution after UCB transplantation [12–14], resulting 
in higher posttransplant infection rates [15]. Strategies to overcome these defects in 
homing and engraftment are clearly needed in order to make this potentially cura-
tive therapy more effective for patients. Additionally, such strategies might apply to 
other types of hematopoietic stem cell (HSC) transplantation, including autologous 
stem cell transplantation as well as allogeneic stem cell transplantation.
Homing is the first process by which circulating hematopoietic cells actively 
cross the blood/BM endothelium barrier to migrate into the BM compartment 
(Figure 1) [16]. This process is fairly rapid and occurs within hours and no longer 
than a day or two after stem cell infusion [16]. HSC homing is mediated in part by 
the binding of chemokine CXCR4 receptor on the surface of HSCs to their ligand, 
stromal cell-derived factor-1 (SDF-1) expressed by BM stromal cells [17]. Stem cell 
homing precedes engraftment, corresponding to proliferation and differentiation 
of hematopoietic stem cells (HSCs) to produce mature, functional hematopoietic 
cells within the BM [18]. One study claimed that only 18–20% of all intravenously 
transplanted stem cells, including different subsets, seeded in the BM, with UCB 
stem cell seeding even lower [19]. Another study demonstrated that human UCB 
stem cell seeding efficiency in NOD/SCID mice was found to be less than that for 
BM (4.4% versus 20%) [20].
2. Current methods to improve UCB HSPC homing
Due to the curative potential of UCB transplantation, several approaches have 
been investigated to improve UCB stem cell homing to the BM. In one study inhibi-
tion of CD26 peptidase activity by pretreating purified CD34+ human CB cells with 
Figure 1. 
Hematopoietic stem/progenitor cell (HSPC) homing to the bone marrow. This process is mediated by CXCR4 
receptors on the surface of HSPCs and stromal cell-derived factor-1 (SDF-1) in the bone marrow.
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Diprotin A significantly enhanced engraftment of HSCs from human UCB into 
NOD/SCID mice [21]. A CD26 peptidase inhibitor, sitagliptin, was investigated in a 
clinical trial with encouraging results in engraftment of adults with hematological 
malignancies after using a single unit UCB transplant [22]. Another strategy taken 
involved direct intrabone administration of cord blood cells into the superior-
posterior iliac crest under rapid general anesthesia. Though this strategy produced 
impressive results in one study [23], another study showed contradictory results 
[24]. Therefore this procedure has not been widely accepted. In exploring further 
defects in cord blood stem cell homing, it was found that cord blood CD34+ cells 
have reduced alpha(1,3)-fucosyltransferase (FucT) expression and activity causing 
a depletion of cord blood stem cell surface ligands necessary for interaction with 
adhesion molecules at time of stem cell homing [25]. Forcing fucosylation was 
found to be clinically feasible with encouraging engraftment efficiency data in the 
double UCB transplant setting [26]. Some of these interventions require significant 
logistical support, and some require graft manipulation; accordingly, there is an 
urgent need to identify safe and practical interventions to enhance UCB homing 
and engraftment for patients with hematologic malignancies who are undergoing 
allogeneic stem cell transplantation.
3.  Pre-clinical data supporting HBO role in modulating EPO/EPOR 
signaling in HSCs
Previously published work implicating erythropoietin (EPO) in HSC homing 
led investigators to examine the role of EPO/EPOR signaling in HSC homing and 
engraftment in vitro and in vivo pre-clinical models. Gonzalez et al. demonstrated 
that circulating HSCs rapidly decline after birth [27]. Interestingly, the decline in 
HSCs correlated with low EPO blood concentration. Additionally, the decline in 
HSCs being attributed to HSC BM homing, these observations suggested a possible 
role for EPO in BM homing and clearance of HSCs from the infant’s circulation 
following birth. Investigators have pursued HBO as a potentially safe approach 
to effectively lower EPO as previously published [28]. The hypothesis was that 
lowering EPO at the time of hematopoietic stem/progenitor cell (HSPC) infu-
sion will result in improved bone marrow homing and subsequent engraftment. 
Studies examining HBOT effects on hematopoietic stem cells are limited. On the 
other hand, HBOT has been shown to have minimal, if any, effects on blood counts 
during steady-state conditions [29]. The previously published and accumulated 
pre-clinical data that supports EPO’s role in UCB engraftment are summarized in 
the next section [30].
To understand EPO effects on UCB CD34+, the expression of EPOR was assessed 
by flow cytometry. Analyses of 5 UCB units revealed that on average 6.5% of CD34+ 
UCB cells express EPOR [30]. A significantly higher percentage of EPOR positive 
cells (45.7 ± 1.4%, Figure 2) was observed within the HSC (Lin− CD34+ CD38− 
CD45RA− CD90+ CD49f+ cells) population. EPOR positive cells were less among 
multipotent progenitor (MPP) (Lin− CD34+ CD38− CD45RA− CD90− CD49f− cells, 
22.2 ± 0.3%) or the broader progenitor pool (Lin−CD34+CD38+ cells, 25.1 ± 0.7%). 
To test whether a functional EPO-EPOR signaling cascade was activated in EPOR-
expressing UCB CD34+ cells, EPOR expression was depleted via RNA interference 
(RNAi), and the erythroid differentiation potential after culture in methylcellulose 
culture medium was compared to UCB CD34+ cells without EPOR depletion. 
Depletion of EPOR expression by RNAi greatly reduced the size of erythroid colo-
nies and UCB CD34+ differentiation potential toward the erythroid lineage, indicat-
ing that EPO promotes functional EPO-EPOR signaling response in these cells [30].
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As earlier studies potentially implicated EPO signaling in hematopoietic stem/
progenitor cell (HSPC) homing [27], investigators tested if there were EPO-EPOR 
signaling effects on SDF-1-induced migration of UCB CD34+ HSPC, by examining 
UCB CD34+ CD38− cell transmigration toward an SDF-1 gradient after a preexpo-
sure of the cells to different concentrations of EPO. Exposure of UCB CD34+ CD38− 
to EPO significantly reduced their SDF-1-induced directional migration. Blocking 
EPO signaling by anti-EPOR or anti-EPO antibodies rescued SDF-1-induced migra-
tion of UCB CD34+ cells for both CD34+ CD38− and CD34+ CD38+ populations [30].
HBO treatment has been shown to reduce systemic EPO levels in healthy volun-
teers [28]. As previous in vitro studies indicated that EPO-EPOR signaling inhibits 
SDF-1-induced migration of UCB CD34+ cells, investigators examined whether 
HBO pre-treatment of mice prior to cell infusion enhances BM homing. First, inves-
tigators measured serum EPO levels in their murine transplant model 7 hours after 
HBO exposure (or 3 hours post UCB CD34+ infusion). HBO exposure significantly 
reduced serum EPO levels compared to controls (p < 0.0001). In addition, a higher 
percentage of the UCB CD34+ cells was seen in the BM of HBO-treated mice 3 hours 
posttransplant [30].
In the same murine model, investigators evaluated the impact of HBO 
treatment on peripheral blood, BM, and spleen retention at early time points 
(24–72 hours), which correlates with BM homing, and up to 4.5 months, 
which correlates with long-term engraftment. Efficient support of human cell 
engraftment has been reported in 6–8-week-old female NSG mice NOD/SCID/
IL-2Rgcnull [31] model. Briefly, sublethally irradiated NSG mice, after 24 hours, 
were treated with HBO for 2 hours (HBO) or without HBO in the control group. 
Next, approximately 105 CD34-selected UCB cells were infused into each mouse 
6 hours following the start of HBO. Mice were euthanized at different time 
points; peripheral blood, BM, and spleen tissue were harvested; and engraftment 
was analyzed by flow cytometry. The degree of engraftment was determined by 
measuring the percentage of human CD45-expressing cells. For HBO therapy, 
100% oxygen was delivered at 2.5 atmospheres absolute (ATA) in a single-place 
chamber. In murine in vivo model, HBO-treated mice had significantly improved 
BM (p = 0.0067), peripheral blood (p = 0.0131), and spleen (p = 0.0293) engraft-
ment [32], the impact of which was more pronounced toward later time points at 
3 and 4 months.
Figure 2. 
Erythropoietin receptor expression on umbilical cord blood CD34+ cells and subsets (unpublished data).
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EPO has been shown to impact hematopoietic progenitor cells differentiation [33]. 
Because HBOT lowers EPO levels in posttransplant, the impact of a low EPO 
environment induced by HBO on human UCB CD34+ cell differentiation was 
examined. HBO mice demonstrated significantly lower numbers of burst-forming 
unit-erythroid (BFU-E) (p = 0.043) and increasing numbers of colony-forming 
unit-granulocyte/macrophage (CFU-G/M) (p = 0.05) 1 week following transplant. 
Interestingly, despite reduced BFU-E in the in vivo experiments, investigators 
observed a favorable trend in red blood cell (RBC) time to transfusion indepen-
dence (TTI) in their pilot study.
These findings suggest that lowering the recipient EPO levels favors UCB CD34+ 
engraftment by affecting two important HSC functions: BM homing and HSPC 
differentiation (Figure 3). Lower recipient EPO at the time of UCB CD34+ cell infu-
sion results in less early erythroid differentiation of infused progenitor cells. This 
leads to early homing of undifferentiated UCB CD34+ cells to the BM, thus improv-
ing long-term multi-lineage engraftment. In confirmatory experiments utilizing 
Figure 3. 
The mechanisms by which hyperbaric oxygen therapy (HBO) affects hematopoietic stem/progenitor cell 
engraftment.
Figure 4. 
Gene expression data analysis evaluating erythropoietin (EPO) treatment effects on UCB CD34+ cells. 
EPO treatment enriches CD71+ early erythroid cells (A) and correlates with active STAT3 signaling (B) 
(unpublished data).
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RNA-seq for transcriptional assessment, investigators found that EPO treatment of 
UCB CD34+ cells enriches CD71+ early erythroid cells, consistent with early ery-
throid commitment (Figure 4). In the same data set, EPO treatment was associated 
with signal transducer and activator of transcription 3 (STAT3) pathway activation 
(Figure 4). Importantly, signal transducer and activator of transcription 3 (STAT3) 
is a known downstream effector of EPOR signal transduction [34–37].
4. Pilot clinical data supporting HBO role in HSC transplantation
To date, two pilot clinical trials exploring HBO in UCB transplantation as well 
as autologous hematopoietic cell transplantation (HCT) have been completed. 
In both studies HBO was given in standard fashion at least 6 hours prior to HSCP 
infusion on day 0 of their transplant (Figure 5). The first aim of these studies is to 
examine the safety and tolerability of HBO in the setting of HCT. In addition, these 
studies explored the impact of HBO on blood count recovery as well as EPO levels 
posttransplant. Details of HBO therapy and the results of these studies are being 
summarized in the next three paragraphs.
4.1 Details of HBO therapy
After receiving routine clinical care on day 0 (the day of HSPC infusion), sub-
jects were exposed to HBO for a total of 90 min after compression to 2.5 atmosphere 
absolutes (ATA) in a monoplace hyperbaric chamber (Model 3200/3200R, Sechrist 
Industries, Inc., USA), breathing 100% oxygen. The subjects spent 10–15 min 
during the compression and decompression phases and 10 min room air breaks for 
every 30 min of HBO treatment.
4.2 HBO in UCB transplantation
Based on the previously mentioned pre-clinical data, a pilot clinical trial  
investigating the safety of HBO in UCB transplant was initiated. Patients considered 
Figure 5. 
Clinical trial schema incorporating hyperbaric oxygen (HBO) into hematopoietic cell transplantation.
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for either standard myeloablative conditioning (MAC) (higher intensity chemo-
therapy and radiation) or standard reduced intensity conditioning (RIC) (lesser 
intensity chemotherapy and radiation) UCB transplantation were enrolled. In this 
study, HBO treatment was administered on day 0 of the transplant. The treatment 
consisted of exposure to 100% oxygen at 2.5 ATA for a total of 2 hours, in a single 
see-through hyperbaric chamber. Six hours from the start of HBO, single or double 
UCB units are infused, and patients are followed daily for toxicity and blood count 
recovery. In addition to safety, neutrophil and platelet recovery and engraftment 
were investigated as efficacy end points. A total of 15 subjects have been treated; all 
have tolerated the procedure very well except for 1 patient who did not finish the 
last 10 min of therapy because of nausea thought to be secondary to a concomitant 
medication. In terms of efficacy, final data from the study indicate an encouraging 
median time to neutrophil recovery of 14 days compared to 20.5 in historic data 
(n = 48) and a median time to platelet count recovery of 37.5 compared to 38 in 
historic data (Table 1). HBO also resulted in improved day 100 survival (p = 0.051) 
and in improvement in the percentage of patients who demonstrated Neutrophil 
recovery was not significant platelet count recovery (p = 0.013). HBO also resulted 
in statistically significant reduction in median EPO level from baseline (−30.37 mU/
ml+/−31.68, p = 0.004).
In a follow-up study, the long-term outcome of patients in this pilot HBO 
study in UCB transplantation was examined. Patients’ outcome was compared 
to a historic control group. The 6-month survival in the HBO group was 100%, 
compared to 67.0% in the control group (95% CI 50.1–79.4%, p < 0.0001) [38]. 
HBO-treated patients had on average lower relapse and non-relapse mortality 
rates, and less chronic graft-versus-host disease (GVHD), but had increased acute 
GVHD. However, these differences were not statistically significant, probably 
because of the small sample size. In the HBO-treated cohort, immune-reconstitu-
tion analysis showed significant improvement in early B-cell recovery, with a trend 
toward improvement in early NK cell recovery. The ratio of 8 hours to baseline 
EPO levels was examined. A nonsignificant trend toward lower EPO values was 
found in those who did not relapse or die in year 1 than those who did die or relapse. 
Disease progression-free survival was also improved in those who had more than 
80% reduction in EPO levels in response to HBO. This study highlights the long-
term safety of HBO therapy when used prior to UCB transplantation. It also shows 
a relationship between HBO-induced EPO reduction, early NK cell recovery and 
posttransplant disease progression. Since lower rates of relapse have been reported 
in association with higher early NK cell recovery [39], it was hypothesized that by 
reducing EPO, HBO improves early NK cell recovery, and improved NK cell recov-
ery slows down disease progression.
HBO 
(n = 15)
Historic 
(n = 48)
p value
Neutrophil recovery (n/%) No 0% 6 (12%) NS
Yes 15 (100%) 42 (82%)
Platelet recovery (n/%) No 0% 15 (31%) 0.013
Yes 15 (100%) 33 (69%)
Median time to neutrophil recovery (range) 14 (6–45) 20.5 (571) NS
Median time to platelet recovery (range) 37.5 (0–85) 38 (0–161) NS
Table 1. 
Blood count recovery in umbilical cord blood transplantation pilot study utilizing hyperbaric oxygen (HBO).
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4.3 HBO in autologous HCT
Encouraged by the results of HBO in UCB transplantation, the same group 
conducted a pilot study in Auto-HSPC transplantation. A total of 20 patients were 
treated on the Auto-HSPC transplant study. HBO therapy was very well tolerated 
as 19 completed full therapy [40]. For efficacy comparison, HBO subjects were 
matched to historical controls from the same institution based on gender, age 
(within 5 years), disease type (multiple myeloma or lymphoma), and preparative 
regimen. The median time to neutrophil count recovery was 11 days in both cohorts, 
the HBO and control cohorts. However, time to neutrophil recovery was approxi-
mately 1 day sooner for HBO than historical controls taking into account the full 
distribution estimates of Kaplan-Meier estimator (log rank p = 0.005). The median 
time to platelet count recovery was 16 versus 18 days for the HBO and control 
cohorts, respectively (log rank p < 0.0001).
In a separate analysis, HBO effects on other outcomes of post-autologous trans-
plantation were evaluated. In this analysis, the HBO cohort patients who completed 
HBO therapy (n = 19) were compared with historic patients (n = 225) [40]. The 
average days of GCSF use were 6 days in the HBO cohort compared to 8 days in 
controls (p < 0.01). Also, HBO patients had significantly less mucositis (26.3 versus 
64.2%, p < 0.01).
5. HBO and stem cell mobilization
In the previous section, the effects of HBO on stem cell homing and engraftment 
posttransplant were reviewed. Interestingly, HBO can also help with stem cell/pro-
genitor cell mobilization from the bone marrow [41]. However, the mobilized stem/
progenitor cells exhibited characteristics of endothelial progenitor cells [42].
6. Current and future prospective
Incorporating HBO into HCT backbone represents a new direction in the field 
of HCT aiming at improving the outcome of HCT by improving HSPC homing 
and subsequent engraftment. Accumulated data suggest improvement in immune 
reconstitution too. Targeting EPO at the time of HSPC infusion represents a new 
understanding of EPO role in basic HSCP functions, including cell differentiation, 
transmigration, homing, and engraftment. Though these studies represent an early 
attempt at understanding EPO role in HSCP biologic functions and HBO’s role 
in blocking EPO/EPOR signaling in HCT transplantation, the accumulated data 
seem to be promising. Currently, a phase II study investigating HBO in Auto-HCT 
is open for enrollment (ClinicalTrials.gov Identifier: NCT03398200). Another 
phase II study investigating HBO in UCB transplantation is expected to be open 
for enrollment in early 2019 (ClinicalTrials.gov Identifier: NCT03739502). Both 
of these studies are randomized prospective clinical trials that focus on investigat-
ing HBO effects on time to neutrophil recovery, platelet count recovery, blood 
and platelet transfusion requirements, and growth factor use. Additionally, both 
studies will be evaluating disease response posttransplant. Immune reconstitution 
will be examined in an attempt to correlate that to disease response posttransplant, 
hypothesizing that HBOT improves immune reconstitution which in turn will result 
in improved disease response to transplant. Finally, these studies will examine HBO 
effects on EPO and IL-15 levels posttransplant. The study in UCB transplantation 
will also focus on time to achieving full-donor chimerism as that might influence 
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disease control posttransplant. This wave of phase II studies will be essential in 
establishing the efficacy of such procedure in HCT and might lead to future phase 
III studies.
An additional area for future investigation is defining the optimal HBO schedule 
to effectively block EPO/EPOR signaling during HCT. In a previous study, one 
single HBO treatment 6 hours prior to HSPC infusion was used. It was noticed 
that EPO level rebounds as early as 24 hours after HBO treatment [30]; accord-
ingly additional HBO therapy might keep EPO levels low for 48 hours, which is the 
duration during which homing occurs. To accomplish that, investigators will have to 
treat the recipients 24 hours after HSPC infusion, which means the infused HSPCs 
will be exposed to hyperbaric conditions. In their experience, direct CD34+ cell 
exposure to HBO reduced their proliferation, impaired their in vitro transmigra-
tion, and reduced their erythroid differentiation [43]. These effects were statisti-
cally significant, but the biological effects were minimal which in theory should 
not influence UCB CD34+ cell behavior significantly. Additionally, these direct 
HBO effects on UCB CD34+ cells are desirable when it comes to the HSPCs that have 
already homed to the bone marrow as these effects might help with HSPC retention 
in the bone marrow.
Finally, in addition to reducing EPO and affecting EPO/EPOR signaling, HBO 
might have additional effects beyond EPO/EPOR signaling that might impact HSPC 
biologic functions.
7. Conclusions
Targeting EPO using HBO in hematopoietic cell transplantation is a new direc-
tion in the HCT field which will potentially have major impact on the outcome 
of HCT. By improving HSPC homing, engraftment, and immune reconstitution, 
HBO therapy will have the potential to improve the outcome of HCT by improving 
patient recovery and by reducing posttransplant complications related to infec-
tions. Overall, that might reduce the cost of HCT. Though data from pre-clinical 
and pilot clinical studies are encouraging, data from current and future phase II 
studies might show more definitive data in support of this application. Also future 
studies will be needed to examine HBO effects on bone marrow microenviron-
ment elements.
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